# Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison.

- **DOI:** [10.1007/s12325-026-03605-4](https://doi.org/10.1007/s12325-026-03605-4)
- **Rating:** Limited (2.7 out of 5)
- **Verdict:** A clinically relevant indirect comparison finds faster resolution with rhC1-INH, but contradictory significance reporting and unresolved cross-trial confounding undermine robustness.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.1007%2Fs12325-026-03605-4

## Key claims

1. rhC1-INH was associated with a statistically significant 4.5-fold increased likelihood of achieving complete resolution (HR 4.52; 95% CI 2.84-7.18) and a significant 82% reduction in redosing (OR 0.18; 95% CI 0.06-0.53) vs sebetralstat.
   - Support: Tentative
   - Type: Primary finding
   - Basis: unanchored MAIC with unmatched severity and treatment timing, plus a non-significant anchored scenario
   - Location: Abstract, Results
2. Supportive analyses provided similar results, with 100% favoring rhC1-INH and 75% achieving statistical significance.
   - Support: Tentative
   - Type: Secondary
   - Basis: one anchored scenario crossed the null despite prose calling it statistically significant
   - Location: Conclusions

## Strengths

- **Clinically relevant comparative endpoints and doses** The analysis compares FDA-approved doses and focuses on complete resolution and redosing, outcomes presented as more decision-relevant than onset of symptom relief.
  - Dimension: contribution
  - Location: Introduction, final paragraph; Discussion, paragraph 3
- **Cross-trial differences are explicitly documented** Tables 2 and 3 identify major differences in treatment setting, attack severity, treatment timing, and redosing protocols rather than treating the source trials as directly interchangeable.
  - Dimension: methodological rigour
  - Location: Results, Feasibility Assessment; Tables 2–3
- **Conflicting prior evidence receives substantive engagement** The Discussion directly addresses a 2025 ITC and specifies differences in endpoint mapping, anchoring, matching variables, and sebetralstat dose.
  - Dimension: positioning
  - Location: Discussion, paragraph addressing the 2025 ITC

## Limitations

- **Scenario significance is reported incorrectly** The Scenario Analyses prose states that both intervention-permissive comparisons were statistically significant, while Table 4 gives confidence intervals crossing the null for TTCR and redosing. This undermines the reported consistency of supportive analyses.
  - Dimension: reporting
  - Location: Results, Scenario Analyses; Table 4
- **Primary comparison retains major confounding** The unanchored MAIC could not match attack severity or treatment timing because the trial populations had minimal overlap. Subgroup analyses explore these differences but do not remove the underlying cross-trial confounding.
  - Dimension: methodological rigour
  - Location: Results, Feasibility Assessment and Subgroup Analyses; Table 3
- **Certainty assessment is not reported** No formal risk-of-bias tool or GRADE-equivalent certainty assessment is reported for the included trials, yet the Conclusions characterize the findings as robust and decision-relevant.
  - Dimension: methodological rigour
  - Location: Methods and Results; Conclusions

## Reliability checks

Concerns (4 of 4 checks).

- **Internal coherence:** Concern. The statistical-significance characterization of the intervention-permissive scenario conflicts with the confidence intervals reported in Table 4. This directly affects the paper's claims that supportive analyses were statistically consistent and robust.
- **Research conduct:** Noted. Ethics requirements and the approvals and consent for the underlying trials are described, but no conflict-of-interest disclosure appears in the supplied article text. No data- or code-availability claim is made.
- **Reference integrity:** Clean. 22 of 22 checkable references verified
  - 28 references in manuscript
  - 6 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17